Munich University Hospital
Munich, Bavaria, 81377, Germany
NCT Number: NCT03079791
The aim of this study is to use the high resolution of optical coherence tomography to assess the prevalence of different types of cardiac allograft vasculopathy (CAV) in cardiac transplanted patients and correlate those results with the level of immunosuppression
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Munich, Bavaria, 81377, Germany
CAV is the most common reason for retransplantation at >1 year and one of the main risk factors for mortality after cardiac transplantation. For this registry, patients planned to undergo coronary angiography either as a part of routine follow-up to screen for relevant cardiac allograft vasculopathy or because of clinical suspicion of relevant cardiac allograft vasculopathy will be considered eligible.
Since the "Transplant Care Guidelines of 2010" recommend the use of intracoronary imaging during angiographic follow-up in patients after heart transplantation to recognize CAV as early as possible, OCT has become integral part of the CAV diagnostic in our center. Through its high resolution OCT (so called virtual histology) provides the earliest possible diagnosis of CAV as well as new insights into the differentiation of CAV types. We aim to correlate the findings of OCT with the level of immunosuppression.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Evaluation of CAV with optical coherence tomography imaging in different follow-up timepoints according to the Heart Transplant Care guidelines
Time frame: 2 years
Association between pattern of CAV and the appropriateness of immunosuppression as measured regularly in routine laboratory
Time frame: 2 years
Combined incidence of death, re-transplantation, myocardial infarction, stroke and coronary revascularization
LMU Klinikum
Other
Prospective Registry of Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT.
Acronym: IMPROVE-OCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03575910
Behavior, Cardiovascular Diseases
Omaha, Nebraska, United States
View Trial DetailsNCT05034354
Biventricular Congestive Heart Failure, Cardiovascular Abnormalities
Edmonton, Alberta, Canada
View Trial DetailsNCT06026215
Cardiovascular Diseases, Heart Diseases
View Trial DetailsNCT05212649
Cardiovascular Diseases, Heart Diseases
Kaohsiung City, Taiwan
View Trial Details